NUBAD, a drug discovery company based in Greenville and founded to bring Clemson University’s chemistry department’s technology to market, announced it has received Small Business Technology Transfer (STTR) matching funds from SCRA Technology Ventures’ SC Launch to develop peptide antibiotic nucleic acids.
With a lab in the Greenville Health’s System’s Institute for Translational Oncology Research (ITOR), NUBAD is working to identify therapies that target nucleic acids and can be used to develop DNA-targeting drugs. The company was accepted to SC Launch in 2012 and founded in 2009.
“We are delighted to announce another SC Launch company receiving SBIR/STTR matching funds from our technology-based economic development program,” said SCRA CEO Bill Mahoney. “The program’s funding match helps South Carolina’s emerging technology companies further commercialize their research, growing our Knowledge Economy. We look forward to the great technologies and contributions that NUBAD will bring to our economy.”
